Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001172452 | SCV000152413 | benign | not specified | 2019-03-07 | criteria provided, single submitter | clinical testing | |
Personalized Diabetes Medicine Program, |
RCV000445414 | SCV000537074 | uncertain significance | Monogenic diabetes | 2015-10-27 | criteria provided, single submitter | research | ACMG Criteria: BP4 |
Fulgent Genetics, |
RCV000764885 | SCV000896045 | uncertain significance | Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome; Pancreatic agenesis 2 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000118081 | SCV001112390 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001103692 | SCV001260484 | benign | Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. |
New York Genome Center | RCV002467566 | SCV002764575 | uncertain significance | Pancreatic agenesis 2 | 2021-02-09 | criteria provided, single submitter | clinical testing |